South Africa pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The archive — 2025
Page 44 of 68 of this archive, newest first.
What the older diet-and-exercise trials found in the hip
Weight loss reduces bone mineral density at load-bearing sites. Whether that translates into fractures in this population is unmeasured.
Six words a verification badge would need to mean anything
The Journal does not treat a badge as evidence and states so wherever it reports one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The consolidator trading as Meridian Freight Partners closes after 17 years
A proper account of an operation that existed, and of what closing it cost.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The lowest effective dose is a real concept with almost no data behind it
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
From cell to clinic: where the extrapolation stops being safe
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Oxidation, and the peroxide that came in with the surfactant
An isoaspartate rearrangement changes the molecule and not the mass. A method that confirms identity by molecular weight alone will report it as the parent compound.
The relabeller trading as Vantris Bio closes after 22 years
A proper account of an operation that existed, and of what closing it cost.
Turkey health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Gallstones during rapid weight loss: drug, or weight loss?
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURMOUNT-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The 21-day notice: how a compounding wind-down works in Switzerland
The document is four pages. Three of them are about dates.
What a laboratory knows about the material it receives
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Resolution, tailing, repeatability: the arithmetic before the result
Matching a retention time against a standard is evidence of consistency, not proof of identity. Two different species can elute at the same time on one method.
Denmark health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
Suzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Germany pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What counts as total, and who decided
We work through a single chromatogram twice, under two integration conventions, and show where the difference comes from.
What TRIUMPH-1 tells us about maintenance, and what it does not
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a QYB dulaglutide lot at 99.3%, against 98.0% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Inspectors cite Halvard & Pike Apothecary of Portland, Maine over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 7-day notice: how a compounding wind-down works in Saudi Arabia
The document is four pages. Three of them are about dates.
Side effects, cost, supply, target: four reasons with four trajectories
The trials studied planned withdrawal. Almost nobody stops that way.